The Autonomous Guardian for Human Longevity
Wearable technology tracks the past and watches you crash. Weyos is a patent-pending, predictive biometric arbitration engine designed to intercept physiological burnout up to four hours before it happens.
Raising £1M pre-seed at a £10M valuation cap
Founded by a former RBS commercial underwriter — £196M cleared, 0% default rate — and a veteran systems architect.
Signal to action
AI decision engine
Don't track the crash. Predict the cure.
A $1.8 trillion wellness market, and health is still getting worse
The 7pm collapse
On Sunday people plan to eat well. By Tuesday evening, brain fog wins and they take the easiest option in front of them.
Longevity is priced for the rich
Functional labs, practitioners and organic living are treated as luxuries, so the people who need prevention most never get it.
Trackers only report the past
Your watch tells you cortisol was high yesterday. It does nothing to change what happens in the next four hours.
Contradictory advice
One source says eat more chickpeas, another says they will bloat you. The result is decision paralysis and abandonment.
Three silos. No one closes the loop.
Everyone measures. Nobody acts.
Oura, Apple Watch, Whoop
Wearables
Measure beautifully. Execute nothing. The insight arrives after the damage.
Calorie and macro trackers
Nutrition apps
Manual logging creates friction, and generic calories ignore your constitution and hormonal phase.
Deliveroo, Amazon Fresh
Delivery platforms
Zero health intelligence. They profit from the exact moment your judgement fails.
Weyos bridges the silos: biometric data from the wearable autonomously triggers logistical execution through retail and delivery, governed by the user's biological blueprint.
We don't guess. We arbitrate.
A patent-pending engine that overrides the plan when the body disagrees
The override formula
Live bio-telemetry
HRV, resting heart rate, sleep depth, skin temperature
Constitutional baseline
A structured constitutional model derived from Ayurvedic typology, cross-referenced against hormonal phase and chronological rhythm — then continuously corrected by live telemetry.
Static schedule
The calendar the user wrote when they felt fine
Vk ≫ Cx > P
Live telemetry always wins. 55 interlocking patent claims filed via Sterne Kessler, Washington D.C.
What that looks like at 3pm
Smartwatch detects a 35% drop in heart rate variability.
The scheduled HIIT session is cancelled before it hurts.
A three-minute cooling breathwork routine is pushed instead.
An anti-inflammatory meal is priced, basketed and one tap from ordered.
Illustrative of the engine's designed behaviour. Beta in development.
Closing the loop
On the roadmap — not yet liveGrocery arbitrage
Designed to scan local budget retailers and build the cheapest basket that fits the user's biological blueprint.
Supplement targeting
Will map functional lab markers to specific, dose-aware supplement cues.
Delivery bypass
Planned as a one-tap healthy option at the exact moment judgement fails.
Beta case study — beta subject, early 50s executive
He assumed he needed digestive enzymes. The engine identified efficient digestion and pointed to cortisol-driven fat retention instead — recommending unplugged walking, targeted L-Theanine and an evening brain dump. Midsection fat shifted in 28 days with no restrictive dieting. Full case study in the data room.
Single-subject beta observation. Not a clinical trial and not medical advice.
As we age, this stops being optional.
The ageing curve creates the demand. The infrastructure just caught up.
The Vampire years
Late nights, poor food, high stress — and no visible consequence. Nothing forces a change.
The debt is called in
Metabolic debt surfaces as burnout, weight that will not move and sleep that does not restore. Generic apps still push harder workouts at people who need recovery.
Non-negotiable
Prevention stops being aspirational and becomes the difference between decades of health and decades of management. This is where willingness to pay becomes near-absolute.
178.9M active wearable users across our launch regions, already streaming the telemetry we need.
HealthKit, FHIR and grocery/delivery APIs are finally mature enough to close the loop automatically.
NHS digital therapeutics tariffs and insurer prevention budgets now pay for outcomes, not apps.
Patent submitted and stealth maintained — the window to lock the synthesis layer is open now.
A £20 billion route to market.
178.9M wearable users today. 347.8M by year seven.
| Region | Today | Year 7 TAM | Target |
|---|---|---|---|
| United Kingdom | 13.4M | 26.0M | 8% |
| United States | 82.5M | 160.0M | 6% |
| Europe (top 5) | 40.0M | 78.0M | 5% |
| United Arab Emirates | 3.0M | 5.8M | 10% |
| India (premium tier) | 40.0M | 78.0M | 5% |
| Total | 178.9M | 347.8M | ~5.8% |
20.06M active users at year seven implies £1.552B ARR. At the 13x–15x multiple typical of enterprise health-tech, that is a £20.2B–£23.3B enterprise valuation. Projections are forward-looking estimates, not guarantees.
The first mile of intent
The core product is free. The majority of revenue sits with the parties who pay when people get sick.
NHS & public health
£30–£50
per managed patient / year
Private insurers
£2–£12
per member / month
Enterprise employers
£5–£8
per employee / month
FMCG retail media
£5–£15
per user / year
Built by underwriters. Defended by patents.
Operators, not visionaries
Pav Masutes
Founder & Chief Executive Officer
A commercial underwriter who cleared over £196 million in corporate finance at RBS across 9,000 fact-finds with a 0% default rate, then bootstrapped mySTAYINN to £9.4 million in revenue without a penny of venture capital.
John Bardis
Chief Technology Officer
A veteran systems architect and engineering leader who has scaled user bases and built multi-modal expert systems, now translating the Weyos biological model into secure AWS infrastructure.
The full founder story, including the operational track record, is inside the data room.
Stealth mode. Patent submitted.
Enter the data room
Use of funds
Finalise the Beta OS
Complete the arbitration engine and ship the closed beta.
Secure API partnerships
Wearable, grocery and delivery integrations required to close the loop.
Launch B2G / NHS pilots
Convert digital therapeutics tariffs into contracted revenue.
These materials are confidential and provided for evaluation only. Nothing here is an offer of securities or financial advice. Early-stage investing carries substantial risk, including the total loss of capital.